Finland’s contributions to medtech are often less recognized than those of its Nordic cousins, Sweden and Denmark. But the country has produced its fair share of industry firsts and while in vitro diagnostics is a particular stronghold of Finland, its medical device innovators are no laggards, according to Medtech Insight’s sister publication, Clinica.

Bristol-Myers’ and AstraZeneca’s deal to acquire Amylin Pharmaceuticals for $7 billion, announced June 29, reaffirms the partners’ commitment to the vast and growing type 2 diabetes market, even if the competition is intense and the companies’ five-year-old alliance got off to a rocky start.

After dropping markedly for two consecutive years, both the number of acquisitions in medical devices and the total dollar volume of those deals jumped significantly in 2003, according to information from Windhover Information's Strategic Transactions Database of industry transactions.

Long part of a German foundation dedicated to improving optical science, Carl Zeiss Meditec has transformed itself into a more entrepreneurial entity, hoping to capitalize on the booming ophthalmics market. For Zeiss, the timing couldn't be better--driven by soaring demographics and new technology, the industry is hot. Plus an industry ripe for consolidation plays well into Zeiss' plans. The only question is: does Zeiss' foundation heritage help or hinder its efforts?